Literature DB >> 30967366

Proteomic evidence of specific IGKV1-8 association with cystic lung light chain deposition disease.

Mylène Camus1,2, Sandrine Hirschi3, Grégoire Prevot4, Marie-Pierre Chenard5, Hervé Mal6, Marc Stern7, Martine Reynaud-Gaubert8, Julia Gilhodes9, Odile Burlet-Schiltz2, Pierre Brousset1,10, Magali Colombat1.   

Abstract

We previously reported a new form of light chain deposition disease (LCDD) presenting as diffuse cystic lung disorder that differs from the usual systemic form with respect to patient age, the male/female ratio, the involved organs, and the hematologic characteristics. We also demonstrated that the light chains were produced by an intrapulmonary B-cell clone and that this clone shared a stereotyped antigen receptor IGHV4-34/IGKV1. However, we only analyzed 3 patients. We conducted a retrospective study including lung tissue samples from 24 patients with pulmonary LCDD (pLCDD) matched with samples from 13 patients with pulmonary κ light chain amyloidosis (pAL amyloidosis) used as controls. Mass spectrometry-based proteomics identified immunoglobulin κ peptides as the main protein component of the tissue deposits in all patients. Interestingly, in pLCDD, IGKV1 was the most common κ family detected (86.4%), and IGKV1-8 was overrepresented compared with pAL amyloidosis (75% vs 11.1%, P = .0033). Furthermore, IGKV1-8 was predominantly associated with a diffuse cystic pattern (94%) in pLCDD. In conclusion, the high frequency of IGKV1-8 usage in cystic pLCDD constitutes an additional feature arguing for a specific entity distinct from the systemic form that preferentially uses IGKV4-1.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30967366     DOI: 10.1182/blood.2019898577

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis.

Authors:  Surbhi Sidana; Surendra Dasari; Taxiarchis V Kourelis; Angela Dispenzieri; David L Murray; Rebecca L King; Ellen D McPhail; Marina Ramirez-Alvarado; Shaji K Kumar; Morie A Gertz
Journal:  Blood Adv       Date:  2021-04-27

2.  [Advances in diagnosis and treatment of monoclonal immunoglobulin deposit disease].

Authors:  J T Zhao; W L Ye; J L Zhuang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

3.  The alterations in molecular markers and signaling pathways in chronic thromboembolic pulmonary hypertension, a study with transcriptome sequencing and bioinformatic analysis.

Authors:  Wenqing Xu; Mei Deng; Xiapei Meng; Xuebiao Sun; Xincao Tao; Dingyi Wang; Shuai Zhang; Yanan Zhen; Xiaopeng Liu; Min Liu
Journal:  Front Cardiovasc Med       Date:  2022-07-26

Review 4.  Randall-Type Monoclonal Immunoglobulin Deposition Disease: New Insights into the Pathogenesis, Diagnosis and Management.

Authors:  Camille Cohen; Florent Joly; Audrey Sibille; Vincent Javaugue; Estelle Desport; Jean-Michel Goujon; Guy Touchard; Jean-Paul Fermand; Christophe Sirac; Frank Bridoux
Journal:  Diagnostics (Basel)       Date:  2021-03-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.